Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Retained Earnings (2022 - 2025)

Corvus Pharmaceuticals has reported Retained Earnings over the past 4 years, most recently at -$400.0 million for Q3 2025.

  • Quarterly results put Retained Earnings at -$400.0 million for Q3 2025, down 3.92% from a year ago — trailing twelve months through Sep 2025 was -$400.0 million (down 3.92% YoY), and the annual figure for FY2024 was -$397.0 million, down 40955.84%.
  • Retained Earnings for Q3 2025 was -$400.0 million at Corvus Pharmaceuticals, down from -$1.1 million in the prior quarter.
  • Over the last five years, Retained Earnings for CRVS hit a ceiling of $2.0 million in Q1 2022 and a floor of -$400.0 million in Q3 2025.
  • Median Retained Earnings over the past 4 years was -$307.7 million (2022), compared with a mean of -$228.9 million.
  • Biggest five-year swings in Retained Earnings: skyrocketed 99.69% in 2023 and later tumbled 40955.84% in 2024.
  • Corvus Pharmaceuticals' Retained Earnings stood at -$307.7 million in 2022, then skyrocketed by 99.69% to -$967000.0 in 2023, then tumbled by 40955.84% to -$397.0 million in 2024, then decreased by 0.75% to -$400.0 million in 2025.
  • The last three reported values for Retained Earnings were -$400.0 million (Q3 2025), -$1.1 million (Q2 2025), and -$381.8 million (Q1 2025) per Business Quant data.